RxDoctor Payments Data

Lawrence Nicastro

Optometrist · Huntsville, ALNPI 1790772655

Payments from drug & device makers

$3,998in general payments, 2019–2025

Across 113 payments — averaging $35.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Coopervision Inc.$732
  • Alcon$536
  • AbbVie$525
  • Sun Pharmaceutical Industries Inc.$485
  • Novartis$292
  • Oyster Point Pharma, Inc.$270
  • plus $1K from 11 others

What the payments were for

  • Food & beverage$3,998100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,998 in reported general payments places this provider in the 85th percentile of 749 optometrist providers in Alabama.

See all optometrist providers in Alabama

Medicare billing

Part B allowed, 2024
$57,295
Medicare patients
379
Services billed
4,599

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost69$26,581
XiidraLifitegrast12$21,556
RestasisCyclosporine22$18,192
CombiganBrimonidine Tartrate/Timolol34$12,818
Travoprost31$6,106
SimbrinzaBrinzolamide/Brimonidine Tart29$5,613
Latanoprost451$4,498
XalatanLatanoprost11$2,857
Loteprednol Etabonate13$1,703
Timolol Maleate44$1,096
Tobramycin-DexamethasoneTobramycin/Dexamethasone14$496
Prednisolone Acetate13$470
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat22$436

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis, Combigan$525$57,591125 claims
Bausch & Lomb Americas Inc.Xiidra$99$21,55612 claims
AlconSimbrinza$536$5,61329 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate$150$1,70313 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 749 optometrist providers in Alabama.

Other optometrist in Huntsville

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →